WRITE: Written Imaginal Thinking Exercise Study
Public ClinicalTrials.gov record NCT07464158. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Written Imaginal Thinking Exercise (WRITE) Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to investigate and compare the effects of three different versions of a future imaginal writing exercise (worst-case scenario, neutral future scenario, best-case scenario) for individuals with elevated social anxiety symptoms. Participants (estimated N=270) will be recruited through the online platform, Prolific, and will be randomly assigned to one of three writing exercise conditions. Participants will complete three study sessions across approximately three weeks. Study session 1 (T1) will consist of baseline assessments and pre-writing ratings, a future imaginal writing exercise, and then post-writing ratings. Study session 2 (T2) will occur approximately one week later and will consist of mid-study assessments and pre-writing ratings, a second, repeated future imaginal writing exercise, and then post-writing ratings. Finally, study session 3 (T3) will occur approximately one week later (approximately two weeks after T1) and will consist of follow-up assessments and repeated post-writing ratings.
Study identification
- NCT ID
- NCT07464158
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 353 participants
Conditions and interventions
Conditions
Interventions
- Worst-Case Scenario Written Exposure Exercise Behavioral
- Neutral Future Scenario Written Exercise Behavioral
- Best-Case Scenario Written Exposure Exercise Behavioral
Behavioral
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2026
- Primary completion
- Jun 4, 2026
- Completion
- Jun 4, 2026
- Last update posted
- Jul 1, 2026
2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Boulder | Boulder | Colorado | 80309 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07464158, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07464158 live on ClinicalTrials.gov.